Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes, Philip J. Mease, Bruce W Kirkham et al. · The Lancet · 2015
Cited by 858 works. doi:10.1016/s0140-6736(15)61134-5
Authors
- Iain B. McInnes
- Philip J. Mease
- Bruce W Kirkham
- Arthur Kavanaugh
- Christopher T. Ritchlin
- Proton Rahman
- Désirée M F M van der Heijde
- Robert Landewé
- Philip G. Conaghan
- Alice Bendix Gottlieb
- Hanno B. Richards
- Luminita Pricop
- Gregory Ligozio
- Manmath Patekar
- Shephard Mpofu
References
- Measurement of patient outcome in arthritis
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- Psoriatic arthritis: epidemiology, clinical features, course, and outcome
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trial
- Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study